Our story

New treatments have to be safe.

Image - Our story

Over the past decades, medicine has made tremendous progress in delivering new life-saving treatments to patients in need.

Inherent to this are side-effects that have frustrated the development of new compounds with great potential or led to withdrawal of already approved drugs from the market. Side-effects can cause harm and even death.

ABS Biotechnologies was founded with the mission to provide patients with safer medicines using our stem cell and cardiovascular expertise. Using IP from a world-leading academic laboratory at the University of Cambridge we strive to eradicate drug-induced heart attacks, strokes, high blood pressure, and irregular heart rhythms.

Our goals are to:

1. Promote patient safety through safer drugs
We use next-generation stem cell technology for rigorous screening of new drug compounds. This prevents exposing patients to harmful side effects

2. Reduce the costs of drug development
Our technology allows for early detection of drug side effects when compounds are still in development so minimising the consequences of side effects emerging during clinical trials or even post-approval. In addition, more accurate testing reduces the risk of erroneously discarding promising candidates during the drug development process.

Our green philosophy

ABS Biotechnologies is committed to measuring and reducing its carbon emissions.

As a company, we will be introducing corporate sustainability principles in our business strategy and operations, which is an essential component in both creating long-term value and achieving our mission of contributing to a safer and healthier world.

Furthermore, ABS Biotechnologies has committed to the 3R model (reduction, refinement and replacement) for avoidance of animal use in research.